Concordance Between Biopsy and Radical Prostatectomy Gleason Scores: Evaluation of Determinants in a Large-Scale Study of Patients Undergoing RARP in Belgium

被引:9
作者
Soenens, C. [1 ]
Dekuyper, P. [1 ]
De Coster, G. [2 ]
Van Damme, N. [2 ]
Van Eycken, E. [2 ]
Quackels, T. [3 ]
Roumeguere, T. [3 ]
Van Cleynenbreugel, B. [4 ]
Joniau, S. [4 ]
Ameye, F. [1 ]
机构
[1] AZ Maria Middelares, Dept Urol, Ghent, Belgium
[2] Belgian Canc Registry, Brussels, Belgium
[3] Erasmus Hosp, Dept Urol, Brussels, Belgium
[4] Univ Hosp Leuven, Dept Urol, Leuven, Belgium
关键词
Prostate cancer; Gleason score; Concordance; Upgrading; Center size; ISUP CONSENSUS CONFERENCE; INTERNATIONAL-SOCIETY; PROSTATIC-CARCINOMA; CANCER; DISCREPANCIES; SPECIMENS; PATTERNS; TRENDS; RISK; MRI;
D O I
10.1007/s12253-020-00860-w
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
To determine whether Gleason scores were concordant between prostate biopsies (bGS) and the definitive resection specimen (pGS) excised with robot-assisted radical prostatectomy (RARP); to identify clinical and pathological factors that might predict upgrading; and to evaluate how upgrading affected outcome. Between 2009 and 2016, 25 Belgian centers participated in collecting prospective data for patients that underwent RARP. We analyzed the concordance rate between the bGS and the pGS in 8021 patients with kappa statistics, and we compared concordance rates from different centers. We assessed the effect of several clinical and pathological factors on the concordance rate with logistic regression analysis. The concordance rate for the entire population was 62.9%. Upgrading from bGS to pGS occurred in 27.3% of patients. The number of biopsies was significantly associated with concordance. Older age (>60 y), a higher clinical T stage (>= cT2), a higher PSA value at the time of biopsy (>10 ng/ml), and more time between the biopsy and the radical prostatectomy were significantly associated with a higher risk of upgrading. Positive margins and PSA relapse occurred more frequently in upgraded patients. Center size did not significantly affect the concordance rate (p = 0.40).This prospective, nationwide analysis demonstrated a Gleason score concordance rate of 62.9%. Upgrading was most frequently observed in the non-concordant group. We identified clinical and pathological factors associated with (non)-concordance. Upgrading was associated with a worse oncological outcome. Center volume was not associated with pathological accuracy.
引用
收藏
页码:2605 / 2612
页数:8
相关论文
共 26 条
[1]   Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study [J].
Ahmed, Hashim U. ;
Bosaily, Ahmed El-Shater ;
Brown, Louise C. ;
Gabe, Rhian ;
Kaplan, Richard ;
Parmar, Mahesh K. ;
Collaco-Moraes, Yolanda ;
Ward, Katie ;
Hindley, Richard G. ;
Freeman, Alex ;
Kirkham, Alex P. ;
Oldroyd, Robert ;
Parker, Chris ;
Emberton, Mark .
LANCET, 2017, 389 (10071) :815-822
[2]   Current trends in patient enrollment for robotic-assisted laparoscopic prostatectomy in Belgium [J].
Albisinni, Simone ;
Joniau, Steven ;
Quackels, Thierry ;
De Coster, Greet ;
Dekuyper, Peter ;
Van Cleynenbreugel, Ben ;
Van Damme, Nancy ;
Van Eycken, Elisabeth ;
Ameye, Filip ;
Roumeguere, Thierry .
CANCER, 2017, 123 (21) :4139-4146
[3]   Interobserver reproducibility of Gleason grading of prostatic carcinoma: General pathologists [J].
Allsbrook, WC ;
Mangold, KA ;
Johnson, MH ;
Lane, RB ;
Lane, CG ;
Epstein, JI .
HUMAN PATHOLOGY, 2001, 32 (01) :81-88
[4]   Upgrade in Gleason score between prostate biopsies and pathology following radical prostatectomy significantly impacts upon the risk of biochemical recurrence [J].
Corcoran, Niall M. ;
Hong, Matthew K. H. ;
Casey, Rowan G. ;
Hurtado-Coll, Antonio ;
Peters, Justin ;
Harewood, Laurence ;
Goldenberg, S. Larry ;
Hovens, Chris M. ;
Costello, Anthony J. ;
Gleave, Martin E. .
BJU INTERNATIONAL, 2011, 108 (8B) :E202-E210
[5]   DEDIFFERENTIATION WITH TIME IN PROSTATE-CANCER AND THE INFLUENCE OF TREATMENT ON THE COURSE OF THE DISEASE [J].
CUMMING, JA ;
RITCHIE, AWS ;
GOODMAN, CM ;
MCINTYRE, MA ;
CHISHOLM, GD .
BRITISH JOURNAL OF UROLOGY, 1990, 65 (03) :271-274
[6]   The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma [J].
Epstein, JI ;
Allsbrook, WC ;
Amin, MB ;
Egevad, LL ;
Bastacky, S ;
Beltrán, AL ;
Berner, A ;
Billis, A ;
Boccon-Gibod, L ;
Cheng, L ;
Civantos, F ;
Cohen, C ;
Cohen, MB ;
Datta, M ;
Davis, C ;
Delahunt, B ;
Delprado, W ;
Eble, JN ;
Foster, CS ;
Furusato, M ;
Gaudin, PB ;
Grignon, DJ ;
Humphrey, PA ;
Iczkowski, KA ;
Jones, EC ;
Lucia, S ;
McCue, PA ;
Nazeer, T ;
Oliva, E ;
Pan, CC ;
Pizov, G ;
Reuter, V ;
Samaratunga, H ;
Sebo, T ;
Sesterhenn, I ;
Shevchuk, M ;
Srigley, JR ;
Suzigan, S ;
Takahashi, H ;
Tamboli, P ;
Tan, PH ;
Têtu, B ;
Tickoo, S ;
Tomaszewski, JE ;
Troncoso, P ;
Tsuzuki, T ;
True, LD ;
van der Kwast, T ;
Wheeler, TM ;
Wojno, KJ .
AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 2005, 29 (09) :1228-1242
[7]   The 2014 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma Definition of Grading Patterns and Proposal for a New Grading System [J].
Epstein, Jonathan I. ;
Egevad, Lars ;
Amin, Mahul B. ;
Delahunt, Brett ;
Srigley, John R. ;
Humphrey, Peter A. .
AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 2016, 40 (02) :244-252
[8]   Gleason group concordance between biopsy and radical prostatectomy specimens: A cohort study from Prostate Cancer Outcome Registry - Victoria [J].
Evans, Sue M. ;
Bandarage, Varuni Patabendi ;
Kronborg, Caroline ;
Earnest, Arul ;
Millar, Jeremy ;
Clouston, David .
PROSTATE INTERNATIONAL, 2016, 4 (04) :145-151
[9]   Evaluating the effect of time from prostate cancer diagnosis to radical prostatectomy on cancer control: Can surgery be postponed safely? [J].
Fossati, Nicola ;
Rossi, Martina Sofia ;
Cucchiara, Vito ;
Gandaglia, Giorgio ;
Dell'Oglio, Paolo ;
Moschini, Marco ;
Suardi, Nazareno ;
Deho, Federico ;
Montorsi, Francesco ;
Schiavina, Riccardo ;
Mottrie, Alexandre ;
Briganti, Alberto .
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2017, 35 (04) :150.e9-150.e15
[10]  
GLEASON DONALD F., 1966, CANCER CHEMO THERAP REP, V50, P125